Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ellis, Levine"'
Autor:
Agnieszka K. Witkiewicz, Emily Schultz, Jianxin Wang, Deanna Hamilton, Ellis Levine, Tracey O’Connor, Erik S. Knudsen
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-17 (2023)
Abstract Despite widespread use and a known mechanism of action for CDK4/6 inhibitors in combination with endocrine therapy, features of disease evolution and determinants of therapeutic response in the real-world setting remain unclear. Here, a coho
Externí odkaz:
https://doaj.org/article/5de605e33d5e4dbfb69355f793daa911
Autor:
Foluso O. Ademuyiwa, Donald W. Northfelt, Tracey O’Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie L. Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S. Hagemann, Michael D. Iglesia, Cynthia X. Ma
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Patients with ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with dual HER2 blockade than ER−/HER2+ BC. Endocrine therapy plus trastuzumab is effective in advanced ER+/HER2+
Externí odkaz:
https://doaj.org/article/49d5c74d8dba4b95b0b0ea0d7e2de4d4
Autor:
Hatem Soliman, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis Levine, Blanche Mavromatis, Jayanthi Srinivasiah, Mohamad Kassar, Robert Gabordi, Rubina Qamar, Sarah Untch, Heather M. Kling, Tina Treece, William Audeh
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Increased usage of genomic risk assessment assays suggests increased reliance on data provided by these assays to guide therapy decisions. The current study aimed to assess the change in treatment decision and physician confidence
Externí odkaz:
https://doaj.org/article/87a37eaf5e5243ac9fe1d0dcb516b31f
Autor:
Pawel Kalinski, Peter Forsyth, Mateusz Opyrchal, Hung Khong, Amy Early, Brian Czerniecki, Shipra Gandhi, Kamran Ahmed, Kristopher Attwood, Ellis Levine, Tracey O’Connor, Robert Fenstermaker, Dheerendra Prasad, Kazuaki Takabe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d199021577a24a39a6ed5e551fe43dc4
Autor:
Ahmad Shariftabrizi, Shalin Kothari, Saby George, Kristopher Attwood, Ellis Levine, Dominick Lamonica
Publikováno v:
The Oncologist. 28:246-251
Background Radium-223 dichloride (Ra-223) is now frequently used to treat prostate cancer that has metastasized to bone, although patient selection continues to be suboptimal for determining who will benefit most from this novel treatment modality. M
Autor:
Shipra Gandhi, Mateusz Opyrchal, Cayla Ford, Ronald Slomba, Kristopher Attwood, Tracey O’Connor, Ellis Levine, Pawel Kalinski
Publikováno v:
Cancer Research. 83:P4-06
BACKGROUND: Pathologic complete response (pCR) or microinvasive residual breast cancer (ypTmic) following neoadjuvant chemotherapy (NAC) is critical for good long-term outcomes in triple negative breast cancer (TNBC) patients (pts) but is achieved on
Autor:
Neeraj Agarwal, Catherine M. Tangen, Maha H.A. Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara, Andrea L. Harzstark, Przemyslaw W. Twardowski, Channing J. Paller, Dylan Zylla, Matthew R. Zibelman, Ellis Levine, Bruce J. Roth, Amir Goldkorn, Daniel A. Vaena, Manish Kohli, Tony Crispino, Nicholas J. Vogelzang, Ian M. Thompson, David I. Quinn
Publikováno v:
Journal of Clinical Oncology. 40:3301-3309
PURPOSE Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic hormone-se
Autor:
Foluso O Ademuyiwa, Donald Northfelt, Tracey O'Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S Hagemann, Cynthia X Ma
Publikováno v:
Cancer Research. 82:P2-13
Background Patients (pts) with ER+ HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after neoadjuvant chemotherapy with dual HER2 blockade than pts with ER- HER2+ BC. Endocrine therapy (ET) plus trastuzumab is
Autor:
Clifford A. Hudis, Nathalie A. Lokker, Sunhee Kwon Ro, Alexander Starr, Rubina Qamar, Diana C. Medgyesy, Ellis Levine, Mark Keaton, Richard Emanuelson, Peter Eisenberg, Jeffrey J. Kirshner, Katherine Bell-McGuinn, Wei Wang, Hope S. Rugo, Edward J. Stepanski, Virginia Kaklamani, J. Thaddeus Beck, Claudine Isaacs, Grace Makari-Judson, Robert C. Hermann, Kurt W. Tauer, Lee S. Schwartzberg
PDF file - 55K, Study Drug Dosing (Safety Population)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c4e3025c6f5aa3ba9893bbb6839078
https://doi.org/10.1158/1078-0432.22447572.v1
https://doi.org/10.1158/1078-0432.22447572.v1
Autor:
Clifford A. Hudis, Nathalie A. Lokker, Sunhee Kwon Ro, Alexander Starr, Rubina Qamar, Diana C. Medgyesy, Ellis Levine, Mark Keaton, Richard Emanuelson, Peter Eisenberg, Jeffrey J. Kirshner, Katherine Bell-McGuinn, Wei Wang, Hope S. Rugo, Edward J. Stepanski, Virginia Kaklamani, J. Thaddeus Beck, Claudine Isaacs, Grace Makari-Judson, Robert C. Hermann, Kurt W. Tauer, Lee S. Schwartzberg
PDF file - 65K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14934968a920e75bea9e145972ac6c53
https://doi.org/10.1158/1078-0432.22447581
https://doi.org/10.1158/1078-0432.22447581